| Mrs Krystal L Lantz, LCP | |
|
1558 Hayes Dr, Manhattan, KS 66502 | |
| (785) 587-4315 | |
| (785) 587-4377 |
| Full Name | Mrs Krystal L Lantz |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 1558 Hayes Dr, Manhattan, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215213186 | NPI | - | NPPES |
| 200742900B | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 1402 (Kansas) | Secondary |
| 101YM0800X | Counselor - Mental Health | 1460 (Kansas) | Primary |
| Entity Name | Pawnee Mental Health Service Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275580524 PECOS PAC ID: 3870406820 Enrollment ID: O20031106000608 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
In patients being treated for heart attack, complete revascularisation of all significantly blocked arteries leads to better outcomes compared to a strategy of unblocking just the "culprit" artery responsible for the heart attack, according to a new study presented today at ESC Congress 2014.
A survey by Mount Sinai School of Medicine researchers has found that 91 percent of physicians believe concerns over malpractice lawsuits result in "defensive medicine," ordering more tests and procedures than necessary as a protective measure. The study, which questioned 2,416 physicians, is published in the June 28 edition of Archives of Internal Medicine.
An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Krystal L Lantz, LCP Po Box 747, Manhattan, KS 66505-0747 Ph: (785) 587-4300 | Mrs Krystal L Lantz, LCP 1558 Hayes Dr, Manhattan, KS 66502 Ph: (785) 587-4315 |
News Archive
Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan-Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, the Company announced that it had reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial in relapsed/refractory multiple myeloma and that the study is expected to start by year-end.
In patients being treated for heart attack, complete revascularisation of all significantly blocked arteries leads to better outcomes compared to a strategy of unblocking just the "culprit" artery responsible for the heart attack, according to a new study presented today at ESC Congress 2014.
A survey by Mount Sinai School of Medicine researchers has found that 91 percent of physicians believe concerns over malpractice lawsuits result in "defensive medicine," ordering more tests and procedures than necessary as a protective measure. The study, which questioned 2,416 physicians, is published in the June 28 edition of Archives of Internal Medicine.
An experimental agent has shown promising results in people with advanced biliary cancer, according to a multi-institutional clinical trial led by cancer researchers at the Ohio State University.
› Verified 8 days ago